Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans

View ORCID ProfileYinong Young-Xu, Gabrielle M. Zwain, Hector S. Izurieta, Caroline Korves, Ethan I. Powell, Jeremy Smith, Abirami S. Balajee, Mark Holodniy, David O. Beenhouwer, Maria C. Rodriguez-Barradas, Sheldon T. Brown, Vincent C. Marconi
doi: https://doi.org/10.1101/2022.01.15.22269360
Yinong Young-Xu
1White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
2Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
MA, MS, ScD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yinong Young-Xu
  • For correspondence: Yinong.Young-Xu{at}va.gov
Gabrielle M. Zwain
1White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
BA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector S. Izurieta
3Food and Drug Administration (FDA), Silver Springs, Maryland
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Korves
1White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
ScD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan I. Powell
1White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
BA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Smith
1White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abirami S. Balajee
1White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Holodniy
4Veterans Affairs Palo Alto Health Care System, Palo Alto, California
5Public Health Program Office, Department of Veterans Affairs, Washington, DC
6Department of Medicine, Stanford University, Stanford, California
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David O. Beenhouwer
7Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California
8Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria C. Rodriguez-Barradas
9Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
10Department of Medicine, Baylor College of Medicine, Houston, Texas
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheldon T. Brown
11Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
12James J. Peters Veterans Affairs Medical Center, Bronx, New York, New York
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent C. Marconi
13Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
14Atlanta Veterans Affairs Medical Center, Atlanta, GA
15Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We estimated vaccine effectiveness (VE) of mRNA vaccines among US Veterans during periods of Delta and Omicron variant dominance. Patients included in this study were largely 65 years or older (62,834, 55%), male (101,259, 88%), and non-Hispanic white (66,986, 58%).

Methods We used SARS-CoV-2 laboratory test results to conduct a matched test-negative case-control study to estimate VE of three and two doses of mRNA vaccines against infection (regardless of symptoms), and a matched case-control study to estimate VE against COVID-19-related hospitalization and death. We estimated VE as (1-odds ratio) x 100%. Severity of disease was measured using hospital length of stay (LOS) and admission to an intensive care unit (ICU).

Results Against infection, booster doses had 7-times higher VE - 59% (95% confidence interval [CI], 57 to 61) - than 2-dose VE (7%; 95% CI, 3 to 10) during the Omicron period. For the Delta period, estimated VE against infection was 90% (95% CI, 88 to 92) among boosted vaccinees, 64% higher than VE among 2-dose vaccinees [55% (95% CI, 51 to 58)]. Against hospitalization, booster dose VE was 87% (95% CI, 80 to 91) during Omicron and 95% (95% CI, 91 to 97) during Delta; the 2-dose VE was 44% (95% CI, 26 to 58) during Omicron and 75% (95% CI, 70 to 80) during Delta. Against death, estimated VE with a booster dose was 94% (95% CI, 85 to 98) during Omicron and 96% (95% CI, 88 to 99) during Delta, while the 2-dose VE was 75% (95% CI, 52 to 87) during Omicron and 93% (95% CI, 85 to 97) during Delta. During the Omicron period, average hospital LOS was 4 days shorter [3 days (95%CI, 3 to 4 days)] than during the Delta period.

Conclusions A mRNA vaccine booster is more effective against infection, hospitalization, and death than 2-dose vaccination among an older male population with comorbidities.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was funded by both the U.S. Food and Drug Administration and the U.S. Department of Veterans Affairs (VA) Office of Rural Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the institutional review board of the Department of Veterans Affairs Medical Center in White River Junction, Vermont, and was granted an exemption for consent because it was deemed impractical.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclaimer: This article represents the authors’ best judgement and should not bind or obligate the VA, the FDA, or any other institution.

  • Conflict of Interest Declaration: YYX, EP, GZ, JS, AB, and CK acknowledge having received funding from Pfizer for other research projects other than this one.

  • Additional authors; additional analyses and results

Data Availability

The data are available upon request to: Clinical Epidemiology Program Veterans Affairs Medical Center 215 North Main Street White River Junction, VT 05009

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted March 13, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans
Yinong Young-Xu, Gabrielle M. Zwain, Hector S. Izurieta, Caroline Korves, Ethan I. Powell, Jeremy Smith, Abirami S. Balajee, Mark Holodniy, David O. Beenhouwer, Maria C. Rodriguez-Barradas, Sheldon T. Brown, Vincent C. Marconi
medRxiv 2022.01.15.22269360; doi: https://doi.org/10.1101/2022.01.15.22269360
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans
Yinong Young-Xu, Gabrielle M. Zwain, Hector S. Izurieta, Caroline Korves, Ethan I. Powell, Jeremy Smith, Abirami S. Balajee, Mark Holodniy, David O. Beenhouwer, Maria C. Rodriguez-Barradas, Sheldon T. Brown, Vincent C. Marconi
medRxiv 2022.01.15.22269360; doi: https://doi.org/10.1101/2022.01.15.22269360

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14627)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)